Systemic Anticoagulation
The best next step in management for this patient is systemic anticoagulation (option a). This patient presents with intermediate-risk (submassive) pulmonary embolism—she is normotensive but demonstrates right ventricular strain with an RV/LV ratio of 1.2, tachycardia, tachypnea, and mild hypoxemia.
Risk Stratification
This patient does not meet criteria for high-risk PE, which requires hemodynamic instability (systolic BP <90 mmHg or drop ≥40 mmHg for >15 minutes, or requiring vasopressor support) 1. Her BP is 108/60 mmHg—she is normotensive. The presence of RV strain (RV/LV ratio 1.2) with preserved blood pressure classifies her as intermediate-risk PE 2, 1.
Key Clinical Features:
- Normotensive (BP 108/60)
- RV strain present (RV/LV ratio 1.2)
- Tachycardia (HR 120/min)
- Hypoxemia responsive to supplemental oxygen
- Bilateral segmental PE on CT
Why Anticoagulation is the Correct Choice
Immediate anticoagulation should be initiated without delay in all patients with confirmed PE 1. For non-high-risk PE patients like this one, anticoagulation is the standard of care 2, 3, 1.
The preferred initial anticoagulation options are 1:
- Low-molecular-weight heparin (LMWH) or fondaparinux for most patients
- Unfractionated heparin if high bleeding risk or severe renal dysfunction (target aPTT 1.5-2.5 times control) 4, 1
Start with weight-adjusted dosing: UFH 80 IU/kg bolus followed by 18 IU/kg/hour infusion 4, or standard LMWH dosing.
Why NOT Thrombolysis Now
Routine use of thrombolytic therapy is not recommended in intermediate-risk PE 2, 1. The 2019 ESC guidelines explicitly state: "Do not routinely administer systemic thrombolysis as primary treatment in patients with intermediate- or low-risk PE" 1.
While thrombolysis may be considered in selected intermediate-risk patients, it should be reserved for those showing clinical deterioration despite anticoagulation 2, 1. The evidence shows:
- Thrombolysis reduces mortality in high-risk PE only (with shock/hypotension) 2
- In intermediate-risk PE, thrombolysis reduces need for escalation but does not reduce overall mortality 2
- Thrombolysis significantly increases major bleeding risk (9.46% vs 3.75%) and intracranial hemorrhage 3
This patient is currently stable on 2L oxygen—there is no indication for immediate thrombolysis. Thrombolysis should be reserved as rescue therapy if she develops hemodynamic deterioration on anticoagulation 1.
Why NOT IVC Filter
IVC filters are not routinely recommended 1. They should only be considered if anticoagulation is absolutely contraindicated due to active bleeding or very high bleeding risk. This patient has no contraindication to anticoagulation.
Clinical Pitfalls to Avoid
Don't be fooled by normal blood pressure alone—RV strain markers indicate intermediate risk, but this does not warrant immediate thrombolysis 2, 1
RV/LV ratio >1.0 is common—one study found 64% prevalence of RV/LV ≥1 in all patients undergoing CT pulmonary angiography, with no significant difference between PE and non-PE patients 5. The ratio of 1.2 indicates strain but not necessarily impending collapse
Monitor closely for deterioration—if the patient develops hypotension, worsening hypoxemia, rising lactate, or shock, then escalate to thrombolysis 1, 6
Address the oral contraceptive—specialist advice should be sought regarding discontinuation of oral contraceptives, which are a reversible risk factor 4
Monitoring Plan
After initiating anticoagulation:
- Check aPTT 4-6 hours after initial bolus if using UFH 4
- Monitor for clinical deterioration requiring escalation
- Transition to oral anticoagulation (preferably a NOAC over warfarin) after at least 5 days when therapeutic 1
- Continue anticoagulation for minimum 3 months; consider indefinite therapy if recurrent or unprovoked 1